Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lefradafiban PK with Pantoprazole in Healthy Subjects
NCT02264106Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 1998
- Primary completion
- Jun 1998
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 1, randomised, open-label trial of lefradafiban in thrombosis and myocardial infarction (MI), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve at steady state, 13th dosing interval at 168 hours, Maximum concentration at steady state, 13th dosing interval at 168 hours and 2 more. Started Apr 1998; status: completed.
02
Drugs
lefradafiban
03
Conditions
thrombosismyocardial infarction (MI)
Beyond the preview
Go deeper on NCT02264106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264106.